5 hours Ago By ABMN Staff
Bicycle Therapeutics ( NASDAQ:BCYC – Free Report ) had its target price reduced by JMP Securities from $32.00 to $26.00 in a research note released on Wednesday morning, Benzinga reports.
They currently have a market outperform rating on the stock. BCYC has been the topic of several other reports. B.
Riley dropped their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th.
Stephens began coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective on the stock.
Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st.
Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock.
Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.25.
View Our Latest Report on Bicycle Therapeutics Bicycle Therapeutics Stock Down 2.1 % Bicycle Therapeutics ( NASDAQ:BCYC – Get Free Report ) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.
74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04.
The firm had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million.
Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%.
The company’s revenue was down 50.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.
26) EPS. Sell-side analysts expect that Bicycle Therapeutics will post -3.05 EPS for the current fiscal year.
Insider Buying and Selling at Bicycle Therapeutics In other news, CEO Kevin Lee sold 3,212 shares of the business’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.
12. Following the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at $8,478,032.64.
The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink .
Also, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.
16. Following the completion of the transaction, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at approximately $483,141.51.
This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here .
Insiders have sold 10,840 shares of company stock valued at $259,128 over the last 90 days. 8.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Bicycle Therapeutics A number of institutional investors have recently added to or reduced their stakes in BCYC. Armistice Capital LLC lifted its holdings in shares of Bicycle Therapeutics by 17.9% in the second quarter.
Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after buying an additional 300,000 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in Bicycle Therapeutics by 21.
5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after purchasing an additional 327,089 shares in the last quarter.
First Light Asset Management LLC lifted its stake in Bicycle Therapeutics by 16.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after purchasing an additional 191,717 shares in the last quarter.
Point72 Asset Management L.P. boosted its holdings in shares of Bicycle Therapeutics by 1,438.
1% during the 3rd quarter. Point72 Asset Management L.P.
now owns 899,799 shares of the company’s stock valued at $20,362,000 after purchasing an additional 841,299 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A.
grew its position in shares of Bicycle Therapeutics by 0.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.
A. now owns 888,081 shares of the company’s stock valued at $17,975,000 after purchasing an additional 4,976 shares in the last quarter. 86.
15% of the stock is owned by hedge funds and other institutional investors. About Bicycle Therapeutics ( Get Free Report ) Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Further Reading Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
